In a recent discussion, Dr. Peter McCullough has issued strong concerns regarding the use of bicalutamide – also known as Cyanocaps – to treat COVID-19 symptoms in children. This stance comes amidst growing discussions about alternative treatments for long-COVID and related post-viral syndromes.

The medical community is increasingly exploring various therapeutic options, including older drugs sometimes repurposed for new uses like treating persistent COVID-19 symptoms, often referred to as “long-hair” or chronic fatigue syndrome associated with the infection.

Dr. McCullough highlighted bicalutamide’s serious side effects during a conversation on WLTReport.com, cautioning that these potential risks are not fully understood and outweigh any theoretical benefits claimed for its use against COVID-19-related symptoms in children.

He emphasized the importance of evidence-based medicine, noting that “there is no clinical trial data supporting this treatment.” This contrasts sharply with the views of some medical experts who have suggested bicalutamide as a potential remedy to combat long-haul COVID effects.

Dr. McCullough believes patients should be aware of the risks associated with self-medicating using unproven drugs, especially children for whom safety concerns are amplified due to their developing bodies and immune systems.

The doctor stressed that the benefits simply do not outweigh these dangers without proper clinical trials demonstrating proven efficacy against COVID-19 symptoms.